CZ20023903A3 - Nová amorfní forma sertralin hydrochloridu - Google Patents

Nová amorfní forma sertralin hydrochloridu Download PDF

Info

Publication number
CZ20023903A3
CZ20023903A3 CZ20023903A CZ20023903A CZ20023903A3 CZ 20023903 A3 CZ20023903 A3 CZ 20023903A3 CZ 20023903 A CZ20023903 A CZ 20023903A CZ 20023903 A CZ20023903 A CZ 20023903A CZ 20023903 A3 CZ20023903 A3 CZ 20023903A3
Authority
CZ
Czechia
Prior art keywords
sertraline hydrochloride
solvent
amorphous form
suitable solvent
process according
Prior art date
Application number
CZ20023903A
Other languages
Czech (cs)
English (en)
Inventor
Brij Khera
Amit Rohatgi
Om Dutt Tyagi
Yatendra Kumar
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of CZ20023903A3 publication Critical patent/CZ20023903A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CZ20023903A 2000-05-26 2001-05-24 Nová amorfní forma sertralin hydrochloridu CZ20023903A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN540DE2000 IN192343B (cg-RX-API-DMAC7.html) 2000-05-26 2000-05-26

Publications (1)

Publication Number Publication Date
CZ20023903A3 true CZ20023903A3 (cs) 2003-05-14

Family

ID=11097055

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20023903A CZ20023903A3 (cs) 2000-05-26 2001-05-24 Nová amorfní forma sertralin hydrochloridu

Country Status (11)

Country Link
US (1) US20040063792A1 (cg-RX-API-DMAC7.html)
EP (1) EP1289928A4 (cg-RX-API-DMAC7.html)
JP (1) JP2003534310A (cg-RX-API-DMAC7.html)
CN (1) CN1438989A (cg-RX-API-DMAC7.html)
AU (1) AU2001256595A1 (cg-RX-API-DMAC7.html)
BR (1) BR0111193A (cg-RX-API-DMAC7.html)
CA (1) CA2409856A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20023903A3 (cg-RX-API-DMAC7.html)
IN (1) IN192343B (cg-RX-API-DMAC7.html)
SK (1) SK17272002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001090049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
PL356452A1 (en) 1999-12-21 2004-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
WO2002096859A1 (en) * 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
CA2483569A1 (en) 2002-04-29 2003-11-13 Tamar Nidam Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
US7186863B2 (en) 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
US7189876B2 (en) 2003-07-15 2007-03-13 Recordati Industria Chimica E Farmaceutica S.P.A. Methods for preparing sertraline hydrochloride polymorphs
US7173153B2 (en) * 2003-07-15 2007-02-06 Recordati Industria Chimica E. Farmaceutica S.P.A. Sertraline hydrochloride form II and methods for the preparation thereof
US20060270859A1 (en) * 2005-01-27 2006-11-30 Santiago Ini Duloxetine HCl polymorphs
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
DE102008039271A1 (de) * 2007-12-23 2009-06-25 Euromed Sa Neuer Mariendistelextrakt, Verfahren zur Herstellung und Verwendung
CN103442572A (zh) * 2011-01-21 2013-12-11 艾利丹尼森公司 含有葡萄糖酸洗必泰的粘合剂
WO2012158483A2 (en) 2011-05-16 2012-11-22 Avery Dennison Corporation Adhesive containing microparticles
CN105073934B (zh) 2013-02-07 2021-12-28 艾利丹尼森公司 具有改进性质的抗微生物粘合剂
EP2968014B1 (en) 2013-03-15 2019-04-24 Avery Dennison Corporation Transparent cover dressing application system and inclusion of label strip
US11337940B2 (en) 2014-06-05 2022-05-24 Avery Dennison Corporation Articles with active agent concentrated at the substrate contacting surface and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
JP2000026378A (ja) * 1998-07-03 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンの製法
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
EP1133459B1 (en) * 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
TWI260315B (en) * 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride

Also Published As

Publication number Publication date
JP2003534310A (ja) 2003-11-18
US20040063792A1 (en) 2004-04-01
BR0111193A (pt) 2003-07-29
AU2001256595A1 (en) 2001-12-03
CN1438989A (zh) 2003-08-27
IN192343B (cg-RX-API-DMAC7.html) 2004-04-10
EP1289928A1 (en) 2003-03-12
SK17272002A3 (sk) 2003-05-02
EP1289928A4 (en) 2005-06-08
CA2409856A1 (en) 2001-11-29
WO2001090049A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
CZ20023903A3 (cs) Nová amorfní forma sertralin hydrochloridu
US8258327B2 (en) Crystalline minocycline base and processes for its preparation
WO2011161690A1 (en) Processes for the preparation of (+)-n,n-dimethyl-2-[1-(naphthalenyloxy) ethyl] benzene methanamine and intermediates thereof
WO2016059507A1 (en) Improved process for the preparation of high pure metformine
US11434206B2 (en) Process for the preparation of diphenylpyrazine derivatives
WO2009062036A2 (en) Processes for preparing levocetirizine and pharmaceutically acceptable salts thereof
WO2011158249A1 (en) Process for preparation of milnacipran intermediate and its use in preparation of pure milnacipran
US20090149662A1 (en) Processes for preparing zafirlukast
US20070100143A1 (en) Crystalline alfuzosin base
US20090202647A1 (en) Solid form of racemic rotigotine
AU2017343384B2 (en) Method for isolation and purification of naltrexone
US20060142574A1 (en) Process for the preparation of ganciclovir
TW202304867A (zh) 經取代二胺基吡𠯤二羧酸之純化
US20060252789A1 (en) Amorphous moxifloxacin hydrochloride
WO2006035291A1 (en) Crystalline forms of cefdinir potassium
US20080146809A1 (en) Process for the Preparation of Novel Amorphous Montelukast Sodium
US10308611B2 (en) Process for the preparation of Lorcaserin hydrochloride
US20060241305A1 (en) Amorphous form of losartan potassium
WO2015145302A1 (en) An improved process for the preparation of exametazime
WO2008053304A2 (en) Processes for the preparation of a stable polymorphic form of entacapone
TW201323407A (zh) 製備６－氯－２，３，４，９－四氫－１ｈ－咔唑－１－羧醯胺及其中間產物之方法